 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- M9140 / EMD Serono
First-in-human trial of M9140, an anti-CEACAM5 antibody drug conjugate (ADC) with exatecan payload, in patients (pts) with metastatic colorectal cancer (mCRC). (Hall D1) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2163;
P1
Contrary to approved ADCs with Top1i payloads, no ILD or ocular toxicities were observed. Evaluation of M9140 in mCRC continues in the dose expansion part of this study.
- PF-08046050 / Sanofi, Pfizer
An open-label phase 1 study to investigate SGNCEACAM5C/SAR445953 in adults with advanced solid tumors (SGNCEA5C-001). (Hall A; Poster Bd #: 305a) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2131;
P1
5. Baudat 2024.
- || M9140 / EMD Serono
Trial completion date, Trial primary completion date, Metastases: Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01) (clinicaltrials.gov) - Mar 27, 2024
P1, N=180, Recruiting, Sponsor: EMD Serono Research & Development Institute, Inc.
Baudat 2024. Trial completion date: May 2025 --> Feb 2026 | Trial primary completion date: Apr 2024 --> Feb 2026
- || M9140 / EMD Serono
Enrollment change, Trial completion date, Trial primary completion date, Metastases: Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01) (clinicaltrials.gov) - Mar 3, 2024
P1, N=180, Recruiting, Sponsor: EMD Serono Research & Development Institute, Inc.
Trial completion date: May 2025 --> Feb 2026 | Trial primary completion date: Apr 2024 --> Feb 2026 N=31 --> 180 | Trial completion date: Nov 2023 --> May 2025 | Trial primary completion date: Nov 2023 --> Apr 2024
- || M9140 / EMD Serono
New P1 trial, Metastases: Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01) (clinicaltrials.gov) - Jul 19, 2022
P1, N=30, Recruiting, Sponsor: EMD Serono Research & Development Institute, Inc.